FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 358 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Durvalumab Extends Lives of People with Early-Stage Small Cell Lung Cancer June 25, 2024 Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway... July 15, 2026 Opinion: ‘Medical research charities are falling through the cracks of COVID-19... June 16, 2020 Load more HOT NEWS Merging the Histologic and Molecular Data Into an Integrated Score Significantly... 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma Cancer target missed for 55,000 patients over 6 years
